Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Dermatol Ther
; 35(4): e15303, 2022 04.
Article
in En
| MEDLINE
| ID: mdl-34984792
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urticaria
/
Anti-Allergic Agents
/
Chronic Urticaria
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Dermatol Ther
Journal subject:
DERMATOLOGIA
Year:
2022
Document type:
Article
Affiliation country: